TABLE 4.

Clinical trials with pazopanib in ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose of pazopanib	Results
NCT01610206 (Duska et al., 2020)	2020	II	148, (gemcitabine alone group n = 73, gemcitabine plus pazopanib group n = 75)	800 mg orally daily	Gemcitabine alone group, gemcitabine plus pazopanib group: PFS 2.9, 5.3 months; OS 1.3, 1.1 years, respectively
CTRI/2017/10/010219 (Sharma et al., 2021)	2021	II	75, (etoposide and cyclophosphamide group n = 38, etoposide and cyclophosphamide plus pazopanib group n = 37)	400 mg once daily	Etoposide and cyclophosphamide group, etoposide and cyclophosphamide plus pazopanib group: PFS 3.4, 5.1 months; OS 11.2 months, not reached, respectively
TAPAZ (Joly et al., 2022)	2022	II	116, (paclitaxel plus pazopanib group n = 79, paclitaxel only group n = 37)	600 mg/day orally	Paclitaxel plus pazopanib group, paclitaxel only group: PFS 4.9, 5.8 moths; OS 13.6, 12.9 months, respectively
PAZOFOS (Morgan et al., 2020)	2020	Ib/II	Ib: 12, (pazopanib plus fosbretabulin group n = 12) II: 21, (pazopanib only group n = 10, pazopanib plus fosbretabulin group n = 11)	Ib: 600 mg once daily (level 1), 800 mg once daily (level 2) II: 800 mg once daily (pazopanib only group n = 10), 600 mg once daily (pazopanib plus fosbretabulin group n = 11)	II. Pazopanib only group, pazopanib plus fosbretabulin group: PFS 3.7, 7.6 months, OS 8.4 months, not reached, respectively

PFS, progression-free survival; OS, overall survival.